Conference Coverage Grant for 2026 ESMO-GI: Hepatocellular Carcinoma
AstraZeneca funds accredited education programs delivering updates from the 2026 ESMO-GI congress on hepatocellular carcinoma to US clinicians, focusing on the latest research and clinical advances.
Funder: AstraZeneca United States
Due Dates: Rolling (applications reviewed and approved on a rolling basis)
Funding Amounts: Up to $150,000–$200,000 total program budget; multi-support acceptable.
Summary: Grant supports independent medical education programs delivering practical updates from the 2026 ESMO-GI congress on hepatocellular carcinoma to US clinicians.
Key Information: Program must be accredited, non-promotional, and fully compliant with ACCME and FDA guidance.
Description
This grant opportunity from AstraZeneca United States supports independent medical education initiatives that provide US-based clinicians with evidence-based, practical updates on the latest research and clinical findings in hepatocellular carcinoma (HCC) presented at the 2026 ESMO-GI congress. The goal is to address the increasing complexity of HCC management due to advances in immunotherapy and emerging treatment strategies, ensuring clinicians are informed about new efficacy and safety data, real-world applicability, and best practices for patient care. Eligible educational formats include live or virtual events, interactive videos, podcasts, simulations, and other digital learning tools that facilitate timely dissemination and contextualization of international congress outputs for US healthcare professionals.
